The present invention provides, inter alia, compounds capable of inhibiting NF-κB. Pharmaceutical compositions containing and methods of using the compounds are also provided herein.
Tosylmethylisocyanide (TosMIC) [3+2] cycloaddition reactions: A facile Van Leusen protocol for the synthesis of the new class of spirooxazolines, spiropyrrolines and Chromeno[3,4-c]pyrrols
The reactivity and chemo-, regio- and diastreo-selectivity of tosylmethyl isocyanides (TosMIC) are investigated in Van Leusen type [3 + 2] cycloaddition reactions with the various activate cyclic ketones and double CCbonds in the synthesis of spirooxazolines, spiropyrrolines and chromeno[3,4-c]pyrrols in good to excellent yields under catalyst-free conditions without any activation at ambient temperature
在Van Leusen型[3 + 2]环加成反应中研究了甲苯磺酰基甲基异氰化物(TosMIC)的反应性和化学选择性,区域选择性和二异丁烯二选择性,其中螺环恶唑啉,螺吡咯啉和chromeno [3,4- c ]吡咯在无催化剂条件下的收率好至极好,在环境温度下没有任何活化作用。
Small molecule NF-κB inhibitors
申请人:ImmuneTarget, Inc.
公开号:US10226464B2
公开(公告)日:2019-03-12
The present invention provides, inter alia, compounds capable of inhibiting NF-κB. Pharmaceutical compositions containing and methods of using the compounds are also provided herein.
Methods of treating cancer with small molecule NF-κB inhibitors
申请人:ImmuneTarget, Inc.
公开号:US11083729B2
公开(公告)日:2021-08-10
The present invention provides, inter alia, compounds capable of inhibiting NF-κB. Pharmaceutical compositions containing and methods of using the compounds are also provided herein. Also provided are methods and kits for treating cancer and solid tumors in a subject, as well as methods and kits for inducing cancer cell death and apoptosis of a cancer cell, all utilizing the NF-κB inhibitors described herein.
Substituted chromeno[2,3-d]pyrimidines as NF-κB inhibitors
申请人:ImmuneTarget, Inc.
公开号:US11266648B2
公开(公告)日:2022-03-08
The present invention provides, inter alia, compounds of general formula (I) capable of inhibiting NF-κB. Pharmaceutical compositions containing and methods of using the compounds are also provided herein.